This inventor holds 2 USPTO granted patents. Top assignee: Schering Aktiengesellschaft. Active years: 1986.
Company Filing History:
Years Active: 1986
Title: Theodor Senge: Innovator in Prostate Treatment
Introduction
Theodor Senge is a notable inventor based in Munich, Germany. He has made significant contributions to the field of medicine, particularly in the treatment of prostatic hyperplasia. With a total of 2 patents, Senge's work focuses on innovative combinations of pharmaceuticals that enhance treatment efficacy.
Latest Patents
Senge's latest patents include groundbreaking methods for treating prostatic hyperplasia. One patent describes a combination of an aromatase-inhibitor and an antiandrogen, specifically in a weight ratio of 20:1 to 1:1. This combination is useful in prophylaxis and therapy for prostatic hyperplasia, with testolactone as the aromatase-inhibitor and cyproterone acetate as the antiandrogen. Another patent emphasizes the use of aromatase-inhibitors for the prophylaxis and treatment of benign prostatic hyperplasia, highlighting testolactone as a particularly preferred aromatase-inhibitor.
Career Highlights
Theodor Senge is associated with Schering Aktiengesellschaft, a company known for its pharmaceutical innovations. His work has contributed to advancements in therapeutic methods that address significant health issues.
Collaborations
Senge has collaborated with notable colleagues such as Hans-Udo Schweikert and Ulf Tunn, enhancing the impact of his research and innovations.
Conclusion
Theodor Senge's contributions to the field of medicine through his patents and collaborations demonstrate his commitment to improving treatment options for prostatic hyperplasia. His innovative approaches continue to influence the pharmaceutical landscape.